aldosterone and Acute Coronary Syndrome studies

Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.

Research Excerpts

Excerpt	Relevance	Reference
"To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome."	7.85	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. ( Ballantyne, CM; Barter, PJ; Gunzburger, E; Kallend, D; Kittelson, J; Leiter, LA; Leitersdorf, E; McMurray, JJ; Nicholls, SJ; Olsson, AG; Pitts, R; Schwartz, GG; Shah, PK; Tardif, JC, 2017)
"Aldosterone appears to be a main marker of adverse clinical outcome, in accordance with the literature."	5.40	Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. ( Arnone, G; Arnone, MT; Assennato, P; Corrado, E; Mignano, A; Novo, G; Novo, S; Pitruzzella, V; Rotolo, A, 2014)
"Aldosterone was measured at randomization and week 8."	5.39	Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial. ( Bode, C; Braunwald, E; Brunel, PC; Hoffman, EB; Morrow, DA; Prescott, MF; Ren, F; Rifai, N; Scirica, BM; Swedberg, K; Udell, JA, 2013)
"To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome."	3.85	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. ( Ballantyne, CM; Barter, PJ; Gunzburger, E; Kallend, D; Kittelson, J; Leiter, LA; Leitersdorf, E; McMurray, JJ; Nicholls, SJ; Olsson, AG; Pitts, R; Schwartz, GG; Shah, PK; Tardif, JC, 2017)
"Aldosterone appears to be a main marker of adverse clinical outcome, in accordance with the literature."	1.40	Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. ( Arnone, G; Arnone, MT; Assennato, P; Corrado, E; Mignano, A; Novo, G; Novo, S; Pitruzzella, V; Rotolo, A, 2014)
"Aldosterone was measured at randomization and week 8."	1.39	Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial. ( Bode, C; Braunwald, E; Brunel, PC; Hoffman, EB; Morrow, DA; Prescott, MF; Ren, F; Rifai, N; Scirica, BM; Swedberg, K; Udell, JA, 2013)

Research

Studies (4)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change From Baseline for HDL Cholesterol

Composite Endpoint:All Cause Mortality

Incidence of Cardiovascular Mortality and Morbidity

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Udell, JA	1
Morrow, DA	1
Braunwald, E	1
Swedberg, K	1
Bode, C	1
Rifai, N	1
Brunel, PC	1
Prescott, MF	1
Ren, F	1
Hoffman, EB	1
Scirica, BM	1
Mignano, A	1
Pitruzzella, V	1
Arnone, G	1
Arnone, MT	1
Rotolo, A	1
Assennato, P	1
Novo, G	1
Corrado, E	1
Novo, S	1
Pitts, R	1
Gunzburger, E	1
Ballantyne, CM	1
Barter, PJ	1
Kallend, D	1
Leiter, LA	1
Leitersdorf, E	1
Nicholls, SJ	1
Shah, PK	1
Tardif, JC	1
Olsson, AG	1
McMurray, JJ	1
Kittelson, J	1
Schwartz, GG	1
Geft, D	1
Schwartzenberg, S	1
George, J	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome[NCT00658515]	Phase 3	15,871 participants (Actual)	Interventional	2008-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	mg/dL (Least Squares Mean)
Dalcetrapib (RO4607381)	44.96
Placebo	15.60

Intervention	Participants (Count of Participants)
Dalcetrapib (RO4607381)	226
Placebo	229

Number of cardiovascular events per patient per year (NCT00658515)
Timeframe: From date of randomization to first event up to 48 months

Article	Year
Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial. Clinical chemistry, 2013, Volume: 59, Issue:6 Topics: Acute Coronary Syndrome; Aldosterone; Amides; Angiotensin-Converting Enzyme Inhibitors; Down-Regulat	2013
Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. Journal of cardiovascular medicine (Hagerstown, Md.), 2014, Volume: 15, Issue:1 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aldosterone; Arrhythmias, Cardiac; Biomarkers; Chi	2014
Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. Journal of the American Heart Association, 2017, 01-10, Volume: 6, Issue:1 Topics: Acute Coronary Syndrome; Aged; Aldosterone; Amides; Angina, Unstable; Anticholesteremic Agents; Card	2017

aldosterone and Acute Coronary Syndrome